181 related articles for article (PubMed ID: 27599351)
21. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine.
Benowitz NL; Swan GE; Jacob P; Lessov-Schlaggar CN; Tyndale RF
Clin Pharmacol Ther; 2006 Nov; 80(5):457-67. PubMed ID: 17112802
[TBL] [Abstract][Full Text] [Related]
22. Disposition kinetics and metabolism of nicotine and cotinine in African American smokers: impact of CYP2A6 genetic variation and enzymatic activity.
Benowitz NL; St Helen G; Dempsey DA; Jacob P; Tyndale RF
Pharmacogenet Genomics; 2016 Jul; 26(7):340-50. PubMed ID: 27035242
[TBL] [Abstract][Full Text] [Related]
23. Effects of whole deletion of CYP2A6 on nicotine metabolism in humans.
Zhang X; Ameno K; Ameno S; Kinoshita H; Kubota T; Kumihashi M; Mostofa J; Iwahashi K; Ijiri I
Drug Chem Toxicol; 2002 May; 25(2):203-13. PubMed ID: 12024803
[TBL] [Abstract][Full Text] [Related]
24. Determinants of the rate of nicotine metabolism and effects on smoking behavior.
Johnstone E; Benowitz N; Cargill A; Jacob R; Hinks L; Day I; Murphy M; Walton R
Clin Pharmacol Ther; 2006 Oct; 80(4):319-30. PubMed ID: 17015050
[TBL] [Abstract][Full Text] [Related]
25. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking.
Rao Y; Hoffmann E; Zia M; Bodin L; Zeman M; Sellers EM; Tyndale RF
Mol Pharmacol; 2000 Oct; 58(4):747-55. PubMed ID: 10999944
[TBL] [Abstract][Full Text] [Related]
26. Low Cotinine Glucuronidation Results in Higher Serum and Saliva Cotinine in African American Compared to White Smokers.
Murphy SE; Sipe CJ; Choi K; Raddatz LM; Koopmeiners JS; Donny EC; Hatsukami DK
Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1093-1099. PubMed ID: 28264876
[No Abstract] [Full Text] [Related]
27. Association of nicotine metabolism and sex with relapse following varenicline and nicotine replacement therapy.
Glatard A; Dobrinas M; Gholamrezaee M; Lubomirov R; Cornuz J; Csajka C; Eap CB
Exp Clin Psychopharmacol; 2017 Oct; 25(5):353-362. PubMed ID: 29048184
[TBL] [Abstract][Full Text] [Related]
28. On-line solid-phase extraction with ultra performance liquid chromatography and tandem mass spectrometry for the detection of nicotine, cotinine and trans-3'-hydroxycotinine in urine to strengthen human biomonitoring and smoking cessation studies.
De Cremer K; Van Overmeire I; Van Loco J
J Pharm Biomed Anal; 2013 Mar; 76():126-33. PubMed ID: 23313774
[TBL] [Abstract][Full Text] [Related]
29. A LC-MS/MS method for concurrent determination of nicotine metabolites and role of CYP2A6 in nicotine metabolism in U937 macrophages: implications in oxidative stress in HIV + smokers.
Jin M; Earla R; Shah A; Earla RL; Gupte R; Mitra AK; Kumar A; Kumar S
J Neuroimmune Pharmacol; 2012 Mar; 7(1):289-99. PubMed ID: 21655912
[TBL] [Abstract][Full Text] [Related]
30. Nicotine and metabolites determination in human plasma by ultra performance liquid chromatography-tandem mass spectrometry: a simple approach for solving contamination problem and clinical application.
Liachenko N; Boulamery A; Simon N
Fundam Clin Pharmacol; 2015 Oct; 29(5):499-509. PubMed ID: 26118829
[TBL] [Abstract][Full Text] [Related]
31. Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence.
Swan GE; Benowitz NL; Lessov CN; Jacob P; Tyndale RF; Wilhelmsen K
Pharmacogenet Genomics; 2005 Feb; 15(2):115-25. PubMed ID: 15861035
[TBL] [Abstract][Full Text] [Related]
32. Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted.
Yamanaka H; Nakajima M; Nishimura K; Yoshida R; Fukami T; Katoh M; Yokoi T
Eur J Pharm Sci; 2004 Aug; 22(5):419-25. PubMed ID: 15265511
[TBL] [Abstract][Full Text] [Related]
33. The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex.
Zhu AZ; Renner CC; Hatsukami DK; Swan GE; Lerman C; Benowitz NL; Tyndale RF
Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):708-18. PubMed ID: 23371292
[TBL] [Abstract][Full Text] [Related]
34. Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake.
Zhu AZ; Zhou Q; Cox LS; Ahluwalia JS; Benowitz NL; Tyndale RF
PLoS One; 2013; 8(8):e70938. PubMed ID: 23936477
[TBL] [Abstract][Full Text] [Related]
35. Nicotine metabolite ratio: Comparison of the three urinary versions to the plasma version and nicotine clearance in three clinical studies.
Giratallah HK; Chenoweth MJ; Addo N; Ahluwalia JS; Cox LS; Lerman C; George TP; Benowitz NL; Tyndale RF
Drug Alcohol Depend; 2021 Jun; 223():108708. PubMed ID: 33873029
[TBL] [Abstract][Full Text] [Related]
36. Population pharmacokinetics of nicotine and its metabolites I. Model development.
Levi M; Dempsey DA; Benowitz NL; Sheiner LB
J Pharmacokinet Pharmacodyn; 2007 Feb; 34(1):5-21. PubMed ID: 17206524
[TBL] [Abstract][Full Text] [Related]
37. Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking.
Benowitz NL; Zevin S; Jacob P
Br J Clin Pharmacol; 1997 Mar; 43(3):259-67. PubMed ID: 9088580
[TBL] [Abstract][Full Text] [Related]
38. Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate.
Lea RA; Dickson S; Benowitz NL
J Anal Toxicol; 2006; 30(6):386-9. PubMed ID: 16872570
[TBL] [Abstract][Full Text] [Related]
39. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans.
Nakajima M; Kwon JT; Tanaka N; Zenta T; Yamamoto Y; Yamamoto H; Yamazaki H; Yamamoto T; Kuroiwa Y; Yokoi T
Clin Pharmacol Ther; 2001 Jan; 69(1):72-8. PubMed ID: 11180041
[TBL] [Abstract][Full Text] [Related]
40. Ethnic differences in nicotine metabolic rate among New Zealanders.
Lea R; Benowitz N; Green M; Fowles J; Vishvanath A; Dickson S; Lea M; Woodward A; Chambers G; Phillips D
N Z Med J; 2005 Dec; 118(1227):U1773. PubMed ID: 16372023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
